linjc16/ctgov huggingface dataset:
Registry of Coronary Artery Ill Patients With Platelet Test Results

Study Overview
=================
Brief Summary
-----------------
ONASSIST is a registry of coronary ill patients who have had a functional test measuring anti-platelet effect and/or a genetic profile of response to anti-platelet drugs.

Detailed Description
-----------------
The Onassist Project is an assistance for cardiologists that establishes an individual risk of stent thrombosis for each patient based on: a functional approach (evaluation of the antiplatelet effect of the antiplatelet regimen by multiple tests) and a pharmacogenomic approach (genetic profile of response to antiplatelet agents) It provides advices for specific therapeutics after identification of adverse drug interactions, treatment compliance issues and true genetic, functional or mixed resistance. This individualized strategy allow to adjust the choice of the drugs and their optimal dosage considering the best benefit - risk ratio. Follow up are regularly made to identify markers of MACE (major adverse cardiac event) or bleeding.

Official Title
-----------------
Online Assistance for Stent Thrombosis

Conditions
-----------------
Acute Coronary Syndrome, Percutaneous Coronary Intervention, Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: coronary disease antiplatelets testing performed as part of usual care and / or gentic profile of antiplatelet response done Exclusion Criteria: patient refusing to be part of the registry

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleeding | all bleeding according to the BARC (Bleeding Academic Research Consortium) definitions are registered during the follow up | 10 years | 
| Myocardial Infarction |  | 10 years | 
| Death |  | 10 years | 
| Stroke |  | 10 years | 
| Urgent Revascularization |  | 10 years | 
| Resuscitated Cardiac Arrest |  | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
antiplatelet, stent thrombosis
Anlotinib Retrospective Study for Esophageal Cancer

Study Overview
=================
Brief Summary
-----------------
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Official Title
-----------------
Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study

Conditions
-----------------
Esophageal Neoplasms

Intervention / Treatment
-----------------
* Drug: Anlotinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Esophageal cancer diagnosed pathologically or clinically Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Anlotinib<br> | Drug: Anlotinib<br>* This is an observational study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression Free Survival | From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | Overall Survival | From date of admission until the date of death from any cause, assessed up to 24 months |
Salivary Diagnostic Testing for IVF

Study Overview
=================
Brief Summary
-----------------
This study aims to determine the performance of a salivary hormone competitive immunoassay for monitoring patients during treatment for infertility.

Detailed Description
-----------------
The goal of this study is to determine the performance of a salivary hormone competitive immunoassay for monitoring patient estrogen and progesterone levels during treatment for infertility using controlled ovarian stimulation (COH) and in vitro fertilization (IVF). Specifically, inter- and intra-assay precision, correlation with serum measurements (the gold-standard), and user satisfaction will be determined. Ultimately, the potential applicability and reliability of salivary steroid monitoring in IVF cycles will be assessed.

Official Title
-----------------
Venopuncture-Free IVF: Can Patient-friendly Salivary Hormone Measurements Replace Serum Monitoring of IVF Patients?

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing In Vitro Fertilization (IVF) at a participating infertility center
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Infertility<br>Patients undergoing ovulation induction and controlled ovarian hyperstimulation at a participating infertility center | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Equivalence of Salivary Steroid Monitoring to Blood Based Monitoring | The potential applicability and reliability of salivary steroid monitoring during infertility treatment will be measured as a progression during a patient's IVF stimulation cycle. Concurrent saliva and blood draw measurements of Estradiol and Progesterone will be taken between 3-5 times during a 2-week monitoring period. Equivalence will be determined by the matched progression of Estradiol and progesterone levels (pg/ml) in the same patient at the concurrent times. Saliva Estradiol and Progesterone levels are of a magnitude of 100-200 less than serum based values and are converted using an algorithm to adjust to serum equivalence. Matched T-test will be used to test the hypothesis that the two methods are not statistically different. | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infertility, In Vitro Fertilization (IVF), Venopuncture-free treatment, Needle-free treatment
Scoring System of Structural Damage for the Hip in Juvenile Idiopathic Arthritis

Study Overview
=================
Brief Summary
-----------------
Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease in children affecting mobility and physical function. The hip involvement represents a frequent complication in JIA patients. The assessment of hip damage becomes a mandatory step in disease monitoring. However, radiological scoring was not standardized. This study aimed to compare the two scoring systems previously proposed, examine their repeatability and their intra and inter agreement.

Official Title
-----------------
Scoring System of Structural Damage for the Hip in Juvenile Idiopathic Arthritis

Conditions
-----------------
Juvenile Idiopathic Arthritis Hip

Intervention / Treatment
-----------------
* Radiation: pelvic radiograph


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All included patient followed the ILAR criteria of JIA and have a hip involvement. This later was defined as the presence of rang motion limitation, and abnormal findings in pelvic radiographic, or ultrasound or MRI in the coxo-femoral joint. Exclusion Criteria: The presence of a contraindication to the performance of conventional radiography any disease affecting cognition Patients who have had surgery on the hip

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intermodality agreement | mesuring the intermodality agreement between two scoring system: the The Childhood Arthritis Radiographic Score of the Hip (CARSH) and the new radiographic scoring system for growth abnormalities and structural change in children with juvenile idiopathic arthritis of the hip | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| interreader agreement | mesuring the interreader agreement between two experimented pediatric rheumatologist for the assessement of structurla damage in JIA hip | 3 months |
Satisfaction, Pain and Function Outcomes of Breast Reduction Patients

Study Overview
=================
Brief Summary
-----------------
To explore the indications and benefits of breast reduction. The investigators suspect all of the patients in this population suffer from neck/back pain and limitations in function. The investigators also want to review the patients in this group to determine if the amount of breast tissue removed or previous breast size affects outcomes for these patients. Patients will then be contacted for outcome data and satisfaction information. Ultimately, this information may lead to improvements in management and education of patients with macromastia.

Official Title
-----------------
Satisfaction, Pain and Function Outcomes of Breast Reduction Patients: A Retrospective Chart Review and Patient Follow up

Conditions
-----------------
Macromastia, Hypertrophy Breast

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females Ages 21-71 years-old Hypertropy of the breast Macromastia post-surgical intervention for macromastia or hypertrophy of the breast Exclusion Criteria: Males BMI>40 Hypertrophy of the breast but without surgical intervention Macromastia but without surgical intervention

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DASH questionnaire | Disabilities of the arm shoulder and hand, pain and function indicators | 6 months | 
| Breast Q questionnaire | quality of life questionnaire | 6 months |
Evaluation of Physician Volumetric Accuracy During Filler Injections

Study Overview
=================
Brief Summary
-----------------
Objectives Evaluate the ability of aesthetic physicians to accurately inject a specific amount (i.e., 0.2cc) of HA soft tissue filler; and Investigate the effect of different HA gel properties (e.g., G', cohesivity, viscoelasticity) on an injector's performance accuracy.

Official Title
-----------------
Evaluation of Physician Volumetric Accuracy During Hyaluronic Acid Soft Tissue Filler Injections and the Effect of Products' Biophysical Properties on an Injector's Performance: An Observational, Proof-of-concept Study

Conditions
-----------------
Injection Site

Intervention / Treatment
-----------------
* Behavioral: Injection of filler material


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Board-certified plastic surgeon, dermatologist, or oculoplastic surgeon. Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Injection of filler material|Subjects will be blind folded and asked to deposit 0.2cc's of each of the four investigational products, in a randomized order. First, over a weight and then into a porcine membrane.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Volumetric accuracy of HA filler injections using observational methods | physicians will attempt to inject 0.2CC of four HA products into a porcine membrane. Volumes will be measured in CC's and their accuracy assessed based on the amount of product left in the syringe. | Baseline | 
| Volumetric accuracy of HA filler expulsions over a scale | Physicians will attempt to dispense 0.2CC of four different HA products. They will do this into free air, over a scale. The weights will be calculated in grams and converted to CC's. The scale is the Smart Weight digital milligram scale, JDS20 edition. It's specifications are as follows: capacity: 20g/100ct/308.8gn/12.86dwt; readability: 0.001g/0.005ct/0.02gn/0.001dwt; scale dimensions: 3x5x0.8; accuracy of 0.001grams and capacity of 20grams. | Baseline |
DDI Study Between Dorzagliatin and Rifampicin

Study Overview
=================
Brief Summary
-----------------
The purpose of this drug-drug interaction study is to investigate the impact of rifampicin on the pharmacokinetics of Dorzagliatin.

Official Title
-----------------
A Single Dose, Open Label, Drug-drug Interaction Study to Investigate the Pharmacokinetics and Safety of Dorzagliation Administered Alone or in Combination With Rifampicin in Healthy Subjects

Conditions
-----------------
Drug Interaction

Intervention / Treatment
-----------------
* Drug: Dorzagliatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body weight ≥ 50 kg (male) or ≥ 45 kg (female) BMI within 19～26 kg/m2 Exclusion Criteria: History or disease status that may impact the ADME of the study Use of any drugs, OTCs, or hebal within 4 weeks of screening Drug abuse Blood donation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequential arm<br>Dorzagliatin was administered single dose; after wash-out, rifampicin was dosed continuously for 9 days, with Dorzagliatin dosed simultaneously on day 8. | Drug: Dorzagliatin<br>* GKA currently under clinical development<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax | Peak plasma concentration | up to 96 hours | 
| AUClast | Area under the plasma concentration curve | up to 96 hours |
Genetic Analysis of Keloids

Study Overview
=================
Brief Summary
-----------------
Keloids have a strong genetic component. The goal of this study is to identify genes and regulatory elements on chromosomes that are the cause for keloids or contribute to keloid scarring.

Detailed Description
-----------------
Keloids are scars that keep growing beyond the border of the original wound. They typically persist for several years, expand for an extensive period of time and are sometimes called benign tumors. Keloids often have a lumpy surface and are often tender, itchy or inflamed around the growing border. Keloids in most keloid patients do not run in the family. In the inheritable form of keloids it is possible that there is one major gene mutation that puts family members at risk for developing keloids. There may be other variations in the DNA (DNA makes up the chromosomes) that determine whether keloids become large and aggressive or stay small and without many symptoms. For this study we will: Send out study participation kits and consent by phone Collect a saliva sample from eligible individuals Obtain information regarding the keloids Document keloids with photos If keloid patients undergo keloid surgery we ask to obtain some scar tissue that would otherwise be discarded Isolate DNA from the saliva sample Perform genetic analyses of the DNA with the most up-to-date methods available to identify genetic variations Study in the laboratory why the genetic variations cause keloids

Official Title
-----------------
Identification of Genetic Variants That Contribute to Keloid Formation in Families and Isolated Cases.

Conditions
-----------------
Keloid

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: keloids; unaffected individuals only if part of a participating keloid family Exclusion Criteria: no keloids; unaffected individuals only as part of a participating keloid family
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| affected<br>individuals with keloids | |
| unaffected<br>unrelated unaffected controls or unaffected family members | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of genetic elements | The goal is to identify relevant genes or genetic elements that cause the disease or contribute to the disease progression and severity. | at time of identification | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
keloid, fibrosis, wound healing, scar
Satiety Effects on the Neural Valuation of Food

Study Overview
=================
Brief Summary
-----------------
Using fMRI, this study will explore the neural correlates of satiety when individuals make decisions about food. The investigators will also examine individual differences in satiety effects.

Official Title
-----------------
Functional Magnetic Resonance Imaging Study of the Valuation of Food as a Function of Satiety

Conditions
-----------------
Fasting, Fed

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chinese ethnicity 21 to 45 years old English as first language Right-handed Have normal eyesight, or have long-sightedness or myopia within +8.0 to -8.0 diopters (unless corrected by contact lenses) Weigh less than 100kg with an abdominal circumference of less than 120cm Non-smoker, or only smoke occasionally (less than 5 sticks a week) Consume less than 2 units (200 mg) of caffeine a day Consume less than 21 units of alcohol per week (e.g. 500ml 5% beer = 2.5 units, 250ml 14% wine = 3.5 unit) Habitually sleep before 1am and wake before 9am Exclusion Criteria: On a restrictive diet (e.g., vegetarian/vegan diet) History of food allergies History of psychiatric or neurological disorders History of chronic medical illness Metal implants in or on the body (e.g. braces, dental retainers, pacemakers) Shift worker Claustrophobic High astigmatism (high = >2.00 diopters) Colour-blind

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low disinhibition<br>fMRI during fed and fasted states | |
| High disinhibition<br>fMRI during fed and fasted states | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fMRI - Willingness to Pay task (BDM auction) | A measurement of how much participants are willing to pay for foods and non-foods, as an assay for subjective value of goods. | Fed and fasted visits (Wks 1 & 2) | 
| fMRI - Monetary and Food Incentive Delay task | A measurement of neural response to anticipating and receiving money and food rewards. | Fed and fasted visits (Wks 1 & 2) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fMRI, Satiety, Willingness to Pay, Incentive Delay, Dietary Disinhibition
Assessment of Hemodynamic Response During Intubation Between Rigid Laryngoscopy and Track Light in Coronary Patients

Study Overview
=================
Brief Summary
-----------------
Opioids provide greater patient comfort during intubation, but are not able to abolish completely the release adrenergic hormones during the laryngoscopy, which may cause undesirable hemodynamic changes. In this study the investigators selected two techniques commonly used for intubation, laryngoscopy and track light, so the investigators can verify which intubation techniques provides less hemodynamic changes in coronary patients under standard anesthesia induction.

Official Title
-----------------
Randomized Clinical Trials to Compare the Hemodynamic Response During Intubation Between Rigid Laryngoscopy and Track Light in Coronary Patients Undergoing CABG

Conditions
-----------------
Coronary Disease Undergoing CABG

Intervention / Treatment
-----------------
* Procedure: laryngoscopy
* Procedure: track light


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: coronary disease ASA 2 e 3 using beta-blockers Exclusion Criteria: emergency surgery arrythmia other antiarrythmic drugs

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Laryngoscopy<br>Laryngoscopy Track Light teaqueal intubation | Procedure: laryngoscopy<br>* tracheal intubation with two different techniques, track light and laryngoscopy.<br>* Other names: rigidy laryngoscopy,;|
| Active Comparator: Track Light<br> | Procedure: track light<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hemodynamic response | tracheal intubation with track light release less adrenergic hormones than laryngoscopy intubation | patient prepare (baseline), 1min after induction, 5 min after induction, 1 min after intubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intubation, coronary disease, hemodynamic response, anesthesia with tracheal intubation, assessment of hemodynamic response